Search
PD1 Combos at ESMO good for AZN and BMY not for MRK and ROG
Chemo combos continue to look equivocal, while IO combos remain durable as MYSTIC’s shadow clears
New ESMO lung cancer data bodes well for Astra’s pivotal IO combo trial MYSTIC and for durable deep responses for Bristol’s IO combo. ESMO also continues to cast doubt over chemo combo’s from Merck and Roche’s 2nd line Tecentriq in Lung
